ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SPRI and Neuromuscular Dynamics Launch NIH-Funded Clinical Trial to Advance Non-Surgical Knee Osteoarthritis Treatment

Vail, Colorado, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) has partnered with Neuromuscular Dynamics, LLC (NMD) to launch a clinical trial evaluating the effectiveness of NMD’s patented “Leg Dexterity System,” a portable, home-based device aimed at improving outcomes for patients with knee osteoarthritis. NMD is based in La Crescenta, California.

Funded by the National Institute on Aging (NIA) at the NIH, the three-year study is being conducted at SPRI’s state-of-the-art Biomotion Laboratory in Vail, Colorado. The trial seeks to determine whether eight weeks of targeted neuromuscular training using the Leg Dexterity System can serve as a viable supplement to nonsurgical treatment, helping patients reduce pain and regain mobility.

The device, developed by NMD co-founder and USC professor Francisco Valero-Cuevas, Ph.D., challenges users to stabilize their foot on an instrumented spring-loaded, unstable platform. This controlled and safe instability activates fast sensorimotor responses that help the leg mediate dynamic contact with the ground, training the effective coordination of muscles around the hip, knee and ankle. A connected tablet sends data to the cloud to be analyzed to enable tracking progress and sharing data with clinicians and participants for ongoing evaluation and treatment.

Together with the principal investigator Erika Valero, an RN with years of clinical and research expertise, Dr. Valero-Cuevas will co-lead the trial alongside Scott Tashman, Ph.D., SPRI’s Director of Biomedical Engineering. The two scientists first collaborated as Ph.D. students in biomechanical engineering at Stanford University studying with the eminent Felix Zajac, and now reunite to explore a promising frontier in osteoarthritis care.

“Francisco has spent years developing innovative approaches to understand the neural control of limbs,” said Dr. Tashman. “This system aligns perfectly with SPRI’s commitment to rigorous, blinded, dose-matched trials that generate actionable insights for patient care for knee osteoarthritis.”

“I’ve long admired SPRI’s leadership in clinical research to change people’s lives for the better,” added Dr. Valero-Cuevas. “We’re excited to take the Leg Dexterity System into a formal trial setting and validate its potential to transform how we manage joint degeneration in individuals who wish to remain active at any age.”

The randomized trial will enroll 84 participants, split evenly between two groups who train at home. One group will train using the Leg Dexterity System’s unstable spring platform, while the comparison group will train using a wobbleboard, which has been shown previously to improve balance and control and provide some benefits for individuals with knee osteoarthritis. Both groups will be guided by app-based tools to encourage and monitor training participation.

Founded in 2015, Neuromuscular Dynamics has already pioneered the first medical device capable of quantifying neuromuscular ability and tracking clinical recovery for fingers and legs. The company hopes this trial will pave the way for widespread adoption of the Leg Dexterity System in physical therapy clinics nationwide within five years.

“Our goal is to offer individuals a home-based non-invasive, user-friendly exercises that specifically promote neuromuscular function in neurological and orthopaedic conditions, such as knee OA,” said Dr. Valero-Cuevas. “This trial is a critical step toward making that vision a reality. Exercise is medicine!”

“At SPRI, we’re driven by innovation in regenerative medicine and rehabilitation,” said Dr. Tashman. “Partnering with Neuromuscular Dynamics allows us to explore new ways to help patients stay active, heal faster and live better.”

 

For further information, contact Marianne Kipp, SPRI’s Director of Marketing & Communications (mkipp@sprivail.org, 970/401-8734)

Attachment


Marianne Kipp
Steadman Philippon Research Institute
970-401-8734
mkipp@sprivail.org

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.